Test study cold plasma treatment for chronic wounds

26.09.2023 12:48

A consortium of three manufacturers will commission and finance the scientific support of the planned test study on cold plasma treatment. The Federal Joint Committee (G-BA) has received a corresponding declaration of intent from the companies neoplas med GmbH, CINOGY System GmbH and Terraplasma GmbH. The three manufacturers want to commission an independent scientific institution (UWI) to prepare, carry out and evaluate the study. This eliminates the need for a procurement procedure to determine a UWI by the G-BA.

The randomized, controlled test study is intended to clarify whether patients with chronic wounds benefit from additional cold plasma treatment if standard treatment has so far been unsuccessful for them. The study will compare the results of this therapy extension with those of standard wound treatment alone. The G-BA has already specified the study design and the central question in a testing guideline.

The cold plasma treatment method has been around for around ten years and is not yet covered by statutory health insurance. Cold atmospheric plasma is applied to the wound in a series of treatments. This is intended to kill (multi-resistant) pathogens that colonize the wound and stimulate the restoration of the destroyed skin. Cold plasma is ionized gas atoms or molecules (for example from argon, oxygen, nitrogen, air or mixtures thereof) that interact with tissue surfaces.

As soon as a UWI is commissioned by the consortium, the G-BA on his website Publish information about this new study.